Autologous Platelet Integrated Concentration (APIC) Injection
The APIC system represents a propriety form of Plasma Rich Platelet Concentration. Cytonics Corporation (www.cytonics.com) has developed a breakthrough molecular technology that concentrates the protein alpha-2-macroglobulin (A2M) within your own blood. This molecule alpha-2-macroglobulin has been shown to specifically inhibit the progression of osteoarthritis by protecting the cartilage from catabolic and inflammatory factors that lead to breakdown within the joint. It is a more specific form of Plasma Rich Platelet therapy, and is specifically used for osteoarthritis. Clinical study has developed a laboratory test to determine who might benefit from this therapy. The FACT™ test is a sample of synovial fluid from the affected joint that measures for the presence of a particular protein called Fibronectin-Aggrecan Complex. The presence of this complex has been shown in clinical studies to be associated with inflammation due to tissue damage or degeneration. Presence of this complex has been associated with a positive response to the APIC procedure. The specific indications for the APIC procedure, frequency, and activity modifications/rehabilitation vary with each condition and physician, and should be discussed specifically with your treating doctor.
How is it performed
A nurse obtains small amount of blood that is drawn into a syringe. This sample then goes through a proprietary centrifugation process (Cytonics corporation) that separates and concentrates the platelets, alpha-2-macroglobulin, and other beneficial growth factors from the blood. This concentrated portion is then injected into the painful joint. The entire APIC procedure is usually done in less than 30 minutes.
What are the risks
Because APIC uses your body’s own natural properties to treat your arthritis side effects are very uncommon. There can be an increase in pain and swelling 48-72 hours after the injection and pain immediately after the injection. These side effects are typically mild and transient.
References
- Arthritis and Rheumatology – July 2014 Identification of α2 -Macroglobulin as a Master Inhibitor of Cartilage-Degrading Factors That Attenuates the Progression of Posttraumatic Osteoarthritis.
- Journal of Bone & Joint Surgery – February 2011 Identification of a Novel Fibronectin –Aggrecan Complex in the Synovial Fluid of Knees With Painful Meniscal Injury
- Cytonics Corporation
It is with a grateful heart that we announce Dr. Anthony Unger’s retirement, effective December 31, 2024. As a founding member of Washington Orthopaedics and Sports Medicine, Dr. Unger has had the privilege of forming lasting relationships with many patients and their families. It has been a true honor for him to provide care across multiple generations, and he deeply values the trust placed in him by so many.